Skip to main content

Creative Biolabs Expands Gene Therapy Solutions with Advanced Oligonucleotide and RNA Technologies

By: Get News
As a global leader in biotech innovation, Creative Biolabs is to utilize state-of-the-art oligonucleotide and RNA technologies to advance the research and development of therapies.

New York, USA - November 24, 2025 - Creative Biolabs, with its extensive experience in molecular biology and drug discovery, continues to provide support to scientists and pharmaceutical companies worldwide by addressing customized service needs that lead to breakthroughs in genetic medicine, thereby accelerating the time to market. The primary focus of these services is on the key areas: custom oligonucleotide synthesis, antisense oligonucleotide synthesis, and reporter circular RNA products.

"Nothing can be compared with the custom oligonucleotide synthesis changing the speed of our study," a molecular diagnostics researcher commented. Creative Biolabs' custom oligonucleotide synthesis service offers high-quality oligonucleotides with precise modifications, facilitating investigations into gene regulation, molecular diagnostics, and targeted therapies.

"To truly revolutionize the custom oligonucleotide service, our top-notch oligonucleotide synthesis platform seamlessly integrates state-of-the-art DNA/RNA synthesizers with high-throughput parallel synthesis technology. This is how we achieve high purity and precision in our custom oligonucleotides," the scientist at Creative Biolabs explained.

The exponential growth of antisense oligonucleotide synthesis has been a topic of widespread discussion lately. Antisense oligonucleotides (ASOs) are gaining increasing recognition as a powerful modality for selected genetic disorders / rare monogenic diseases.

"The pinpoint accuracy of ASOs is very good, but the winning factors are a dependable synthesis and validation," said a pharmaceutical R&D director. Creative Biolabs' proficiency in generating antisense molecules, which form the basis of the most promising therapeutic approaches, is outstanding. They are maximizing efficacy, stability, and delivery through the service utilization of advanced chemical modifications and conjugation techniques.

Numerous experiments have demonstrated that the artificial engineering of circular RNAs (circRNAs) can enhance circularization, translation efficiency, and protein stability. Creative Biolabs offers a complete range of reporter circRNA products, such as:

* Luciferase reporter (LR) circRNA

LR genes, being powerful tools, are utilized for studying gene expression at the transcriptional level. Additionally, they play a crucial role in the investigation of regulatory microRNAs, which are complementary to specific circular RNAs.

* Green fluorescent protein (GFP)-circRNA

Our researchers can tailor GFP-circRNAs to meet the requirements of your research. These products are capable of efficiently expressing reporter proteins without inducing severe cytotoxicity and immunogenicity.

The comprehensive portfolio of Creative Biolabs is the driving force behind innovation for scientists worldwide. By merging impeccable technical skills with a willingness to collaborate, the company is taking a step further in becoming a reliable partner in gene therapy progress.

For more information, please visit https://www.creative-biolabs.com/gene-therapy.

About Creative Biolabs

Creative Biolabs is a global leader in innovative biotech solutions, focusing on advancements in gene therapy by leveraging the latest oligonucleotide and RNA technologies. With the company's strong expertise in molecular biology, drug discovery, and therapeutic development, it has become the most reliable partner for scientists and pharma companies globally.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.28
+5.59 (2.53%)
AAPL  275.92
+4.43 (1.63%)
AMD  215.05
+11.27 (5.53%)
BAC  51.93
+0.37 (0.72%)
GOOG  318.47
+18.82 (6.28%)
META  613.05
+18.80 (3.16%)
MSFT  474.00
+1.88 (0.40%)
NVDA  182.55
+3.67 (2.05%)
ORCL  200.28
+1.52 (0.76%)
TSLA  417.78
+26.69 (6.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.